A cellular conformation-based screen for androgen receptor inhibitors

Area of Science:

• Molecular biology
• Biochemistry
• Pharmacology

Background:

• The androgen receptor (AR) is crucial for physiological processes and implicated in diseases like prostate cancer.
• Current antiandrogen therapies face limitations due to resistance and side effects.
• Novel therapies targeting post-ligand binding events are needed.

Discussion:

• A high-throughput fluorescence resonance energy transfer (FRET) assay was developed to detect ligand-induced AR conformational changes.
• This FRET assay was directly compared against a transcription-based assay using FDA-approved compounds and natural products.
• The FRET assay demonstrated equivalent sensitivity and superior specificity in identifying antiandrogen activities.

Key Insights:

• The FRET assay effectively identifies compounds with previously unrecognized antiandrogen activities.
• This approach enhances the discovery of small molecule AR inhibitors.
• Directly measuring AR conformation change provides a more specific screening method.

Outlook:

• The FRET-based assay can significantly improve the identification of novel antiandrogen drug candidates.
• This technology holds potential for developing more effective treatments for AR-dependent diseases.
• Further application of this assay could accelerate drug discovery for nuclear receptor targets.